Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalisformula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study-Reference-Cited by-同舟云学术

Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalisformula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study

Published:2018-10-20 Issue:12 Volume:93 Page:1467-1473
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Yang Ming-Hua¹,Wan Wu-Qing²,Luo Jie-Si³,Zheng Min-Cui⁴,Huang Ke⁵,Yang Li-Hua⁶,Mai Hui-Rong⁷,Li Jian⁸,Chen Hui-Qin⁹,Sun Xiao-Fei¹⁰,Liu Ri-Yang¹¹,Chen Guo-Hua¹²,Feng Xiaoqin¹³,Ke Zhi-Yong³,Li Bin¹⁴,Tang Yan-Lai³,Huang Li-Bin³,Luo Xue-Qun³^ORCID

Affiliation:

1. Department of Pediatrics; Xiangya Hospital, Central South University; Changsha Hunan China

2. Department of Pediatrics; Second Xiangya Hospital, Central South University; Hunan China

3. Department of Pediatrics; First Affiliated Hospital, Sun Yat-Sen University; Guangzhou China

4. Department of Hematology; Hunan Childdren's Hospital; Changsha Hunan China

5. Department of Pediatrics; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Guangzhou China

6. Department of Pediatrics; Zhujiang Hospital, Southern Medical University; Guangzhou China

7. Department of Hematology and Oncology; Shenzhen Children's Hospital; Shenzhen China

8. Department of Pediatric Hematology; Fujian Medical University Union Hospital; Fuzhou Fujian China

9. Department of Pediatrics; Third Affiliated Hospital, Sun Yat-Sen University; Guangzhou China

10. Department of Pediatrics; Sun Yat-Sen University Cancer Center; Guanzhou China

11. Department of Pediatrics; Huizhou Municipal Central Hospital; Huizhou Guangdong China

12. Department of Pediatrics; First People's Hospital of Huizhou; Huizhou Guangdong China

13. Department of Pediatrics; Nanfang Hospital, Southern Medical University; Guangzhou China

14. Clinical Trials Unit, First Affiliated Hospital, Sun Yat-Sen University; Guangzhou China

Funder

Sun Yat-Sen University Clinical Research 5010 Program

The Science and Technology Planning Project of Guangdong Province, China

The Science and Technology Planning Project of Guangzhou, China

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25271/fullpdf

Reference37 articles.

1. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia;Shen;Proc Natl Acad Sci,2004

2. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial;Burnett;Lancet Oncol,2015

3. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: north American leukemia intergroup study C9710;Powell;Blood,2010

4. Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the Children's oncology group phase III historically controlled trial AAML0631;Kutny;J Clin Oncol,2017

5. Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid;Zhu;Br J Haematol,2016

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishment of XRD fourier fingerprint identification method of realgar decoction pieces and its anti-tumor activity in tumor-in-situ transplanted mice;Journal of Ethnopharmacology;2024-09

2. Analysis of the occurrence and liver function characteristics of arsenic-associated liver injury during the treatment of pediatric patients with acute promyelocytic leukemia;Annals of Hematology;2024-08-21

3. Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy;Hematology, Transfusion and Cell Therapy;2024-05

4. Central venous catheters do not increase the hemorrhagic risk in acute promyelocytic leukemia patients during induction therapy;Frontiers in Oncology;2024-04-12

5. Natural products as potential drug treatments for acute promyelocytic leukemia;Chinese Medicine;2024-04-03